Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran

• Status: Unknown status
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the antiinflammatory effects of rivaroxaban compared with dabigatran in patients with atrial fibrillation.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yokohama City University Medical Center
• Collaborator: Yokohama City University
• Treatments: Anti-Inflammatory Agents; Dabigatran; Rivaroxaban

Criteria

Inclusion Criteria:

• non-valvular atrial fibrillation

• a CHADS2-VASc score of 1 or more

Exclusion Criteria:

• contraindication for rivaroxaban or dabigatran

• stroke or systemic embolism, acute coronary syndromes or peripheral artery disease within 6 months before enrollment

• acute heart failure

• severe chronic renal failure (creatinine clearance < 30mL/min.)

• receiving dual antiplatelet therapy

• patients with a body weight of 50kg or less

• uncontrolled hypertension

• active malignancy, collagen disease, or infectious disease

• patients undergoing surgery within 6 months before enrollment

• patients who are planned to undergoing catheter ablation for atrial fibrillation

• patients who are not allowed to participate in the trial by judgement of the treating physician